SYSTEMATIC REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1658571
This article is part of the Research TopicImmune Predictive and Prognostic Biomarkers in Immuno-Oncology: Refining the Immunological Landscape of CancerView all 35 articles
Prognostic value of platelet to lymphocyte ratio(PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis
Provisionally accepted
- 1Xinjiang Medical University, Ürümqi, China
- 2Cancer Hospital of Xinjiang Medical University, Urumqi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The platelet to lymphocyte ratio ( PLR ) is widely recognized as an important biomarker of systemic inflammation and has been associated with treatment responses in breast cancer (BC) patients undergoing neoadjuvant therapy. However, existing evidence remains inconsistent. This meta-analysis aims to systematically investigate the prognostic value of PLR in BC patients receiving neoadjuvant chemotherapy (NACT).Methods: A broad and systematic search of the literature was carried out using PubMed, Embase, Web of Science, and the Cochrane Library, covering all available records from the inception of each database through April 7, 2025. Study selection was guided by a set of predetermined inclusion and exclusion parameters. Primary outcomes included overall survival (OS), disease-free survival (DFS), and pathological complete response (pCR), assessed through hazard ratios (HRs) or odds ratios (ORs) with corresponding 95% confidence intervals (CIs).Results: Twenty-four studies involving 7,557 BC patients receiving NACT were included. Elevated PLR was significantly associated with reduced pCR rates (HR = 1.51; 95% CI: 1.24-1.84; p < 0.0001; I² = 70%), shorter OS (HR = 1.64; 95% CI: 1.27-2.11; p = 0.0002; I² = 0%), and decreased DFS (HR = 2.29; 95% CI: 1.54-3.39; p < 0.0001; I² = 44%). Subgroup analyses indicated that PLR's prognostic value varied by timing of PLR measurement, geographic location, and PLR cutoff values.Conclusions: Elevated PLR is significantly correlated with poorer clinical outcomes in BC patients undergoing NACT, suggesting its potential as a predictive biomarker for treatment efficacy. However, due to methodological limitations of the included studies, further prospective investigations are required to confirm these findings across diverse populations. Systematic review registration: PROSPERO, identifier CRD420251064051 KEYWORDS platelet to lymphocyte ratio(PLR), BC, NACT, prognostic value of survival, meta-analysis
Keywords: platelet to lymphocyte ratio (PLR), breast cancer, NACT, prognostic value of survival, Meta-analysis
Received: 02 Jul 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Zhao, Xu, Ma and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Binlin Ma, Cancer Hospital of Xinjiang Medical University, Urumqi, China
Chao Dong, Cancer Hospital of Xinjiang Medical University, Urumqi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.